CANSINOBIO (06185) recorded a net loss attributable to shareholders of 40.42 million yuan in the first quarter, a 250.13% increase compared to the same period last year.
Cansino Biologics (06185) announced its performance for the three months ending March 31, 2026. The operating income was 190 million yuan, a year-on-year increase of 38.73%; the net loss attributable to shareholders of the listed company was 40.4243 million yuan, a year-on-year increase of 250.13%; basic loss per share was 0.16 yuan.
CANSINOBIO (06185) released its performance for the three months ending on March 31, 2026, with a revenue of 190 million yuan, a year-on-year increase of 38.73%; a net loss attributable to shareholders of the listed company of 40.42 million yuan, a year-on-year increase of 250.13%; basic loss per share was 0.16 yuan.
Related Articles
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.
UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.
LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.
UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.
LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
